INTRODUCTION AND OBJECTIVES Beta-blocker treatment of stable heart failure in primary care. The objective was to evaluate the feasibility and tolerability of uptitrating beta-blockers in patients with stable systolic heart failure seen in primary care. METHODS Before and after intervention study. The study was conducted in two primary care centers in Barcelona, Spain. Consecutive samples of p...

CONTEXT Calcium channel blocker poisoning is a common and sometimes life-threatening ingestion. OBJECTIVE To evaluate the reported effects of treatments for calcium channel blocker poisoning. The primary outcomes of interest were mortality and hemodynamic parameters. The secondary outcomes included length of stay in hospital, length of stay in intensive care unit, duration of vasopressor use,...

In 1975, Waagstein and colleagues1 published several case reports of patients with heart failure and tachycardia who clinically improved after long-term administration of p-adrenergic antagonists. These initial reports were met with substantial skepticism, since p-blocking agents are negatively inotropic and chronotropic. Their use for treatment of heart failure is counterintuitive and demands ...

Abstract Daytime sleepiness is a cardinal symptom of obstructive sleep apnoea (OSA) and well-recognised side effect beta-blockers, therefore patients with OSA under this treatment may have worse sleepiness. However, the interaction between daytime beta-blockers use has not been thoroughly investigated in before. We analysed data 2183 individuals (1852 331 snorer controls) from 3 countries (Gree...

Foundational therapy for heart failure and a reduced ejection fraction consists of combination an angiotensin receptor–neprilysin inhibitor, beta-blocker, mineralocorticoid receptor antagonist sodium–glucose co-transporter 2 (SGLT2) inhibitor. However, the conventional approach to implementation is based on historically-driven sequence that not strongly evidence-based, typically requires ?6 mon...

Objectives: SMYRNA-HF study is a prospective multicenter registry to determine the profiles of patients with heart failure (HF) in Turkey. This aimed present baseline characteristics preliminary cohort by comparing them according different HF phenotypes. Methods: The first included outpatients from 9 centers. Patients were classified into three phenotypes as reduced ejection fraction (HFrEF), m...

INTRODUCTION Recent data about radiographic progression during treatment with tumor necrosis factor-alpha (TNF-alpha) blocker agents in patients with ankylosing spondylitis (AS) have prompted an intensive discussion about the link between inflammation/bone destruction and new bone formation and the order of events. Therefore, we analysed parameters of cartilage degradation, neoangiogenesis, and...

OBJECTIVES We compared the hemodynamic effects of dobutamine and enoximone administration before and after long-term beta-blocker therapy with metoprolol or carvedilol in patients with chronic heart failure (HF). BACKGROUND Patients with HF on beta-blocker therapy may need hemodynamic support with inotropic agents, and the hemodynamic response may be influenced by both the inotropic agent and t...

Sodium-channel blockers act by slowing sodium influx into myocytes through voltage gated channels. Many substances have sodium-channel blocking properties and many others show this effect when taken in overdose. Sodium-channel blocker poisoning, associated with a high death rate, is characterized by a variety of clinical presentation, depending on the pharmaceutical agent involved. Sodium bicar...